Phase I trial of intratumoral therapy using HF10, an oncolytic HSV-1, demonstrates safety in HSV+/HSV- patients with refractory and superficial cancers.

Robert L. Ferris, Yukihiro Nishiyama, Maki Tanaka et al.|Journal of Clinical Oncology|2014

Cited by 30